Ann: Appendix 4E - Preliminary Final Accounts and Commentary, page-15

First 15 Last

Share
Profile

Follow
HoganHound

1,422 Posts.

94

29/02/20

10:53

Post #: 43231281
Share

Originally posted by DoubleDown!: ↑

For what it's worth I don't think this is a good report. A loss of $25m this year and shares on issue ballooning by 50% to close to 1bn.

Gross margin of only 50% means just to cover employee benefits you need another $20m of revenues. That's more than double.

Loss of goodwill on acquisitions of $3.5m means we've overpaid for something.

Consultants costs you'd hope were in relation to acquisitions and not going to be repeated.

Doubtful debts up by $700k to nearly $1m. Means we're selling goods to people who can't afford to pay us. With revenues of $18m that's 5.5% of sales not being paid for.

I think it's pretty clear that Animoca have expanded way too fast, they cannot handle everything under their umbrella. This company is wildly spinning out of control. A lack of financial control, a lack of regulatory control and management problems are plaguing the company.

They cannot go on like this and stay viable. They need to get their house in order, start generating revenue from their assets, stop the dilution from acquiring underperforming companies and show the shareholders they are in control.

Very fortunate to be in suspension. This report released at this time would see the company share price smashed.

Expand

there is deferred revenue the accounting shows that the company has receipts of 24.9m on a 5m loss

AB1 Price at posting: 18.0¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

First 15 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Ann: Appendix 4E - Preliminary Final Accounts and Commentary, page-15

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Monash IVF shares cater 25% – Disaster or deep-value play?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Australia’s gas crisis is here – and dying coal plants aren’t helping

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News